CDKN2A and central nervous system cancer: Some molecular markers, such as IDH, 1p/19q codeletion, EGFR amplification, CDKN2A/B loss, and TERT promoter mutation, etc. have been routinely tested in clinical practice and cooperated with histopathological information to form the classification scheme of glioma (49).